摘要:
Die Erfindung betrifft einen Kollimator (1) zum Begrenzen eines Bündels energiereicher Strahlen (2), das von einer im wesentlichen punktförmigen Strahlungsquelle (3) ausgehend auf ein Behandlungsobjekt (4) gerichtet ist und insbesondere der stereotaktischen Konformationsbestrahlung von Tumoren dient, wobei der Kollimator (1) als strahlbegrenzendes Mittel eine Irisblende (5) aufweist. Für einen solchen Kollimator (1) wird eine hohe Abschirmung bei geringer Bauhöhe und mit einer variablen Öffnungsgröße der Blendenöffnung (12) dadurch erzielt, daß die Irisblende (5) mindestens drei Blendenblätter (6, 6', 6" oder 7, 7', 7", 7"' oder 8, 8', 8", 8"', 8'''' oder 9, 9', 9", 9"', 9"", 9'"") aufweist, die gleiche Winkel (α) einschließende, aneinanderliegende Seitenflächen (10) aufweisen, wobei die Blendenblätter (6, 6', 6" oder 7, 7', 7'', 7''' oder 8, 8', 8", 8'", 8'''' oder 9, 9', 9", 9''', 9'''', 9''''') eine strahlbegrenzende Öffnung (12) dadurch freigeben, daß eine Schiebebewegung (13) entlang der Seitenflächen (10) durch eine höchstens um eines verminderte Anzahl von Blendenblättem (6, 6', 6" oder 7, 7', 7", 7"' oder 8, 8', 8", 8"', 8"" oder 9, 9', 9", 9"', 9'''', 9''''') stattfindet.
摘要:
The invention relates to a dual-modality imaging system and a method for dual-modality imaging, wherein a positron emission tomography (PET) scanner for acquiring PET imaging data and at least one optical imaging detector for acquiring optical imaging data are arranged to acquire the PET imaging data and the optical imaging data of an imaged object (5) simultaneously.
摘要:
The invention relates to an imaging method for simultaneously determining in vivo distributions of bioluminescent and/or fluorescent markers and radioactive markers at identical projection angles. The distribution of the bioluminescent and/or fluorescent markers is determined by means of at least one first detector separately detecting photons which have a first average energy and are emitted by the bioluminescent and/or fluorescent markers while the distribution of the radioactive markers is determined by means of at least one second detector simultaneously but separately detecting photons which have a second average energy and are emitted by the radioactive markers. The invention also relates to a device for carrying out the inventive imaging method, comprising at least one CCD camera (1, 2) as a first detector, at least one single photon emission computed tomographic (SPECT) detector (3) as a second detector, and a layer (5) which essentially reflects the photons of the bioluminescent and/or fluorescent markers and substantially transmits the photons of the radioactive markers.
摘要:
The present invention relates to an optical scanning device that comprises a light source to emit a beam of light, and a beam splitter to split that beam into several beamlets, and further a first objective lens to direct said beamlets onto a focal plane wherein each of said beamlets impinges on the focal plane spacially separated from each other, wherein the beam splitter comprises at least one birefringent element, preferably a stack of Wollaston prisms.
摘要:
The present invention relate to a vector which is suitable for gene prophylaxis/gene therapy, containing a nucleic acid fragment coding for a mutated prion protein. The invention further relates to a vaccination agent which contains said vector in addition to the usual auxiliary agents, and to the use of said vector or vaccination agent in the prophylaxis and/or treatment of prion diseases. The invention further relates to non-human mammals e.g., working animals, which are resistant to prion infections.
摘要:
The invention relates to retroviral vectors based on feline foamy viruses (FeFV) for introducing a desired expressible DNA into a mammal cell. An example of the inventive vector is a vector which permits the expression of neutralizing epitopes of the feline immunodeficiency virus (FIV) in cats or of the human immunodeficiency virus (HIV) in humans and thus enables an effective vaccination.
摘要:
Described are slow-release pharmaceutical compositions allowing to monitor the course of drug release by non-invasive methods. These compositions comprise - besides a controlled release drug preparation - a detectable agent, wherein said detectable agent has substantially the same release rate as said drug.
摘要:
The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.
摘要:
Described are the peptide motifs QCTEVRADTRPWSGP (human TRP-2 60-74 ), QCTEYRADTTPWSGP (TRP-2 60-74 YT, epitope variant of human TRP-2 60-74 ), LPYWNFATGRNECDV (human TRP-2 242-256 ), SEEILGPDGNTPQFE (human TRP-1 166-180 ), LRRYNADISTFPL (human TRP-1 415-427 ) and related motifs characterizing peptides which are capable of activating CD4+ T helper cells (Th) against a TRP-2 + and/or TRP-1 + tumor, preferably a malignant melanoma or glioma. Moreover, various diagnostic and therapeutic uses of peptides containing said motifs and antibodies directed against said peptides are described.